Interim report H1 2025

Core Insights - The company reported a strong organic sales growth of 9% in the first half of the year, with an upward revision of the full-year guidance to a range of 6-8% [1][3] - Profitability remains solid despite currency headwinds, with an adjusted EBITDA margin of 37.4%, up by 210 basis points compared to the previous quarter [3] - The company achieved cost synergies at a 100% run rate, indicating improved operational efficiency [3] Sales Performance - Organic sales growth in the Food & Health segment reached 10%, while the Planetary Health segment saw a growth of 9% [3] - Emerging markets experienced a robust organic sales growth of 12%, compared to 8% in developed markets [3] Financial Metrics - Adjusted net profit increased by 23%, reflecting strong financial performance [3] - The company maintained a net interest-bearing debt to EBITDA ratio of 2.1x, following the acquisition of dsm-firmenich's part of the Feed Enzyme Alliance [3] Shareholder Returns - A share buyback program worth EUR 100 million was completed on June 27, enhancing shareholder value [3] - An interim dividend of 2.25 DKK (EUR 0.30) was approved for the first half of 2025 [3] Future Outlook - The company has narrowed its 2025 organic sales growth outlook to 6-8%, with a range of 7-9% excluding exits from certain countries [3] - Long-term financial targets for 2030 have been announced, indicating a strategic focus on growth and investment in unique biosolutions [1][3]